Sample records for arsphenamine

  1. Ensaios terapêuticos com penicilina: IV - Bouba - (Framboesia, pian, yaws: tratamento das ulcerações gomosas, periostites, osteites áreas de rarefação óssea e gangoza (Rhinopharyngitis mutilans

    Directory of Open Access Journals (Sweden)

    F. Nery Guimarães


    Full Text Available Six patients of terciary yaws, were treated with Penicillin in small dosis at Evandro Chagas Hospital of the Oswaldo Cruz Institute. The lesions presented by the patients were: gummatous ulcerations, periostitis, osteitis, osteoporosis and gangoza (rhinopharyngitis mutilans. In all cases, clinic recovery were obtained, the time of treatment varying from 2 to 8 months. The total amount of oxford units 'per" subject varied from 48.000 to 586.800 Patients with bone lesions, ever after the treatment, has not showed complete recomposition of the bone structure, ever so aparently healing and with negative sorologics tests. Identical results has been observed in patient showing the same lesions and treated with neo-arsphenamine. The patients are still under observations at the Hospital.

  2. The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize. (United States)

    Bosch, Fèlix; Rosich, Laia


    On the centenary of Paul Ehrlich's Nobel Prize, this German researcher deserves to be remembered as a pioneer in a large number of scientific disciplines. As a result of his enthusiasm and scientific abilities, dedication, and contacts with other scientists of his time, he was able to make countless contributions in fields as diverse as histology, haematology, immunology, oncology, microbiology and pharmacology, among others. Although the Swedish award was meant to recognize the standardization of the manufacture of antidiphtheria serum, it was the discovery of arsphenamine (Salvarsan) for the treatment of syphilis which won him wider international acclaim. From a pharmacological perspective, Ehrlich's outstanding contributions include dissemination of the 'magic bullet' concept for the synthesis of antibacterials, introduction of concepts such as chemoreceptor and chemotherapy, and linking the chemical structure of compounds to their pharmacological activity. These achievements took place within the framework he established for the transition from experimental pharmacology to therapeutic pharmacology. He introduced a modern research system based on the synthesis of multiple chemical structures for pharmacological screening in animal models of disease states. These contributions were undoubtedly decisive in propitiating the wider development of antibiotics decades later. For these reasons, it is fitting to mark the 100th anniversary of the Nobel Prize awarded to this great scientist by commemorating the importance of his contributions to the advance of pharmacology.

  3. The pharmaceutical industry and the German National Socialist Regime: I.G. Farben and pharmacological research. (United States)

    López-Muñoz, F; García-García, P; Alamo, C


    Before the National Socialist party came to power, the German pharmaceutical industry constituted an international reference as far as the development of new medicines was concerned, having been responsible for synthetic analgesics (phenacetin, phenazones, acetylsalicylic acid), arsphenamine, barbiturates and sulfonamides. The year 1925 saw the founding of I.G. Farben (Interessen-Gemeinschaft Farbenindustrie AG), a conglomerate of companies that would monopolize the country's chemical production and come to own all its major pharmaceutical industries. During the World War II, I.G. Farben participated in numerous operations associated with the criminal activities of the Nazi executive, including the use of slave labour in plants built close to concentration camps, such as that at Auschwitz. With regard to medical and pharmacological research projects, I.G. Farben became involved in experimental programmes using patients from the Nazi regime's euthanasia programmes and healthy subjects recruited without their consent from concentration camps, on whom various pharmacological substances were tested, including sulfamide and arsenical derivatives and other preparations whose composition is not precisely known (B-1012, B-1034, 3382 or Rutenol, 3582 or Acridine), generally in relation to the treatment of infectious diseases, such as typhus, erysipelas, scarlet fever or paratyphoid diarrhoea. Furthermore, I.G. Farben played a decisive role in the German army's chemical warfare programme, contributing to the development of the first two neurotoxic substances, later known as 'nerve agents', tabun and sarin. Some of these activities came to light as a result of the one the famous Nuremberg Trials in 1947, which saw 24 executives and scientists from I.G. Farben brought to justice for, among other offences, the use of slave labour in the concentration camps and forced experimentation with drugs on prisoners.